We explored whether silibinin treatment might impact both the secretome for proteins linked to the TGFβ signaling pathway and the activation of SMAD2/3 in ALK–TKI-resistant NSCLC cells. The gene discussed is SMAD2; the disease is non-small cell lung carcinoma.